6-oxaspiro[3.4]octan-2-one | 1638771-98-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢呋喃
• 英文名称: 6-oxaspiro[3.4]octan-2-one
• 英文别名: 6-Oxaspiro[3.4]octan-2-one
• CAS: 1638771-98-8
• 化学式: C₇H₁₀O₂
• 分子量: 126.155
• InChiKey: UKVBQHOYZLCBEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-oxaspiro[3.4]octan-2-one 在 盐酸羟胺 、 溶剂黄146 、 potassium hydroxide 作用下， 以 甲醇 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 N-hydroxy-7-((2s,4s)-6-oxaspiro[3.4]octan-2-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carboxamide
  参考文献：
  名称：

  [EN] HDAC6 INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE HDAC6 ET LEURS UTILISATIONS

  摘要：

  Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.

  公开号：

  WO2023150203A1

文献信息

• 1‐Azaspiro[3.3]heptane as a Bioisostere of Piperidine**
  作者：Alexander A. Kirichok、Hennadii Tkachuk、Yevhenii Kozyriev、Oleh Shablykin、Oleksandr Datsenko、Dmitry Granat、Tetyana Yegorova、Yuliya P. Bas、Vitalii Semirenko、Iryna Pishel、Vladimir Kubyshkin、Dmytro Lesyk、Oleksii Klymenko‐Ulianov、Pavel K. Mykhailiuk

  DOI：10.1002/anie.202311583

  日期：2023.12.18

  1-Azaspiro[3.3]heptanes were synthesized, characterized, and validated biologically as bioisosteres of piperidine. Incorporation of this core into the anesthetic drug bupivacaine instead of the piperidine ring resulted in a patent-free analogue with high activity.

  合成、表征并验证了 1-氮杂螺[3.3]庚烷作为哌啶的生物等排体。将这个核心代替哌啶环掺入麻醉药物布比卡因中，产生了具有高活性的无专利类似物。
• [EN] HDAC6 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE HDAC6 ET LEURS UTILISATIONS
  申请人：[en]EIKONIZO THERAPEUTICS, INC.

  公开号：WO2023150203A1

  公开（公告）日：2023-08-10

  Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.